A detailed history of Royal Bank Of Canada transactions in Cullinan Oncology, Inc. stock. As of the latest transaction made, Royal Bank Of Canada holds 5,535 shares of CGEM stock, worth $74,445. This represents 0.0% of its overall portfolio holdings.

Number of Shares
5,535
Previous 3,688 50.08%
Holding current value
$74,445
Previous $64,000 43.75%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$16.03 - $20.86 $29,607 - $38,528
1,847 Added 50.08%
5,535 $92,000
Q2 2024

Aug 14, 2024

BUY
$15.63 - $29.35 $48,578 - $91,219
3,108 Added 535.86%
3,688 $64,000
Q1 2024

Nov 05, 2024

SELL
$10.17 - $19.02 $31,608 - $59,114
-3,108 Reduced 84.27%
580 $9,000
Q1 2024

May 15, 2024

SELL
$10.17 - $19.02 $84,858 - $158,702
-8,344 Reduced 93.5%
580 $9,000
Q4 2023

Feb 14, 2024

SELL
$7.89 - $10.23 $6,564 - $8,511
-832 Reduced 8.53%
8,924 $90,000
Q3 2023

Nov 14, 2023

BUY
$9.05 - $11.72 $6,923 - $8,965
765 Added 8.51%
9,756 $88,000
Q2 2023

Aug 14, 2023

BUY
$8.8 - $13.4 $65,929 - $100,392
7,492 Added 499.8%
8,991 $96,000
Q1 2023

May 15, 2023

SELL
$10.2 - $11.91 $30,742 - $35,896
-3,014 Reduced 66.78%
1,499 $15,000
Q4 2022

Feb 14, 2023

BUY
$9.72 - $13.62 $40,201 - $56,332
4,136 Added 1097.08%
4,513 $47,000
Q3 2022

Nov 14, 2022

SELL
$11.82 - $15.42 $2,340 - $3,053
-198 Reduced 34.43%
377 $5,000
Q2 2022

Aug 15, 2022

SELL
$7.31 - $13.55 $15,877 - $29,430
-2,172 Reduced 79.07%
575 $7,000
Q1 2022

May 16, 2022

SELL
$10.47 - $16.75 $39,587 - $63,331
-3,781 Reduced 57.92%
2,747 $29,000
Q4 2021

Feb 14, 2022

BUY
$15.36 - $25.0 $57,108 - $92,950
3,718 Added 132.31%
6,528 $101,000
Q3 2021

Nov 15, 2021

BUY
$22.56 - $29.68 $42,931 - $56,481
1,903 Added 209.81%
2,810 $64,000
Q2 2021

Aug 16, 2021

BUY
$24.96 - $41.25 $22,638 - $37,413
907 New
907 $23,000

Others Institutions Holding CGEM

About Cullinan Oncology, Inc.


  • Ticker CGEM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 45,612,200
  • Market Cap $613M
  • Description
  • Cullinan Oncology Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with ...
More about CGEM
Track This Portfolio

Track Royal Bank Of Canada Portfolio

Follow Royal Bank Of Canada and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

News

Stay updated on Royal Bank Of Canada with notifications on news.